Measures of high quality ambulatory care derived from the PQRS

Measure	Eligible Visits					Appropriate Care
	Medical Condition	Exclusions	Age Range, y	No. of patient records	No. of Estimated Patient Visits in Millions
Preventative Care Measures Group
Advising smokers and tobacco users to quit	Smoking and GME	None	≥ 18	1,097	35	Smoking cessation counseling recorded
Body mass index (BMI) screening	All GMEs	None	≥ 18	6,855	264	BMI recorded
Weight reduction counseling during for overweight patients	BMI>25 in patients 18 to 64. BMI>30 in patients >65 and GME	None	≥ 18	2,228	79	Weight reduction counseling recorded
Urinalysis not performed at visit	All GMEs	Urinary symptoms, renal disease, diabetes, HIV/AIDS, hypertension	≥ 18	4,125	159	No urinalysis performed
Diabetes Mellitus (DM) Measures Group
Blood Pressure Management	DM	None	18 to 75	974	28	Blood pressure <140/80
Heart Failure (HF) Measures Group
Angiotensin converting enzyme inhibitor (ACE-I) or Angtiotensin receptor blocker (ARB) therapy	HF	Hyperkalemia and angioedema	≥ 18	558	15	ACE-I or ARB reported as current medication
Beta blocker therapy	HF	Heart block, COPD, Asthma	≥ 18	441	11	Beta-blocker reported as current medication
Coronary Artery Disease (CAD) Measures Group
Oral Antiplatelet therapy	CAD	Peptic ulcer disease, GI bleeding, gastritis, duodenitis, renal disease	≥ 18	1,590	38	Oral platelet aggregation inhibitors or salicylates reported as current medication
Beta blocker therapy	CAD	Heart block, bradycardia, COPD, Asthma	≥ 18	1,462	35	Beta-blocker reported as current medication
Miscellaneous
No antibiotics for upper respiratory infection	Acute bronchitis, Upper respiratory infection	COPD, HIV/AIDS, cancer	18 to 65	378	16	No antibiotic prescribed
Anticoagulation therapy in patients with Atrial Fibrillation (AF)	Atrial fibrillation	Peptic ulcer disease, GI bleeding, gastritis, duodenitis, cerebral hemorrhage, CNS tumors, thrombocytopenia, gait abnormality, bleeding diathesis, abnormal uterine bleeding	≥ 18	529	14	Oral coumarins, heparins, oral thrombin inhibitors, thombin inhibitors, oral factor Xa inhibitors, oral platelet aggregation inhibitors, or salicylates reported as currently taking
Bronchodilator therapy in patients with Chronic Obstructive Pulmonary Disease (COPD)	COPD	None	≥ 18	565	22	Taking adrenergic bronchodilators, bronchodilator combinations, or anticholinergic bronchodilators